Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy

BACKGROUND: Most lethal prostate cancers progress from relapse of aggressive primary disease. Recently, the most significant advances in survival benefit from systemic therapy have come from moving the administration of therapy to an earlier disease state. There is movement toward using biomarkers f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol Focus
Main Authors: VanderWeele, David J., Finney, Richard, Katayama, Kotoe, Gillard, Marc, Paner, Gladell, Imoto, Seiya, Yamaguchi, Rui, Wheeler, David, Lack, Justin, Cam, Maggie, Pontier, Andrea, Minh Nguyen, Yen Thi, Maejima, Kazuhiro, Sasaki-Oku, Aya, Nakano, Kaoru, Tanaka, Hiroko, Griend, Donald Vander, Kubo, Michiaki, Ratain, Mark J., Miyano, Satoru, Nakagawa, Hidewaki
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586528/
https://ncbi.nlm.nih.gov/pubmed/29398457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euf.2018.01.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados